Here’s why the Incannex share price is rocketing 18% today

Incannex provided an update on the APIRx takeover.

| More on:
Rising marijuana share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares accelerate 17.81% to 43 cents 
  • The company entered into a share sale and purchase agreement to acquire APIRx 
  • Completion of the acquisition is subject to a shareholder vote which will be held at the extraordinary general meeting in June 2022 

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move today following a company’s latest acquisition.

At the time of writing, the healthcare company’s shares are trading at 43 cents, up 17.81%.

Incannex progresses on APIRx takeover

According to its release, Incannex announced it has entered into a share sale and purchase agreement to acquire APIRx Pharmaceuticals.

Based in the United States, APIRx is a leading pharmaceutical company specialising in cannabinoid active pharmaceutical ingredients and drug products.

The acquisition will be made by an all-scrip transaction of 218 million Incannex shares at a value of $0.573 per share.

This requires Incannex’s shareholders to approve the issue of the new shares to the sellers under ASX Listing Rule 7.1.

A shareholder vote will be held at the extraordinary general meeting in June 2022.

If green-lit, the shares will be issued at the completion of the acquisition and thus APIRx will become a wholly-owned subsidiary of the company.

Incannex noted that the acquisition of APIRx delivers a strong portfolio of patented drug candidates. This includes 22 development programs covering a total addressable market of US$400 billion per annum.

Together, Incannex and APIRx will form the world’s largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols.

The takeover is expected to be seamless, as APIRx’s assets are similar to Incannex’s operational capabilities and pharmaceutical development strategy.

Incannex CEO and managing director, Joel Latham commented:

The acquisition of APIRx presents us with clear long and short-term opportunities for significant value growth. Several drug candidates have shortened regulatory pathways to break into areas of patient need representing very large global markets. These candidates are our initial development priority.

Incannex’s strong cash position allows us to pursue these near-term product opportunities at the same time as moving at pace to develop the Incannex combination drug candidates. Once the acquisition of APIRx has been finalised, Incannex will have many diverse projects under development, the progress over which we will update the stock exchanges with ongoingly.

Incannex share price snapshot

Over the past 12 months, the Incannex share price has surged close to 60%.

While investor optimism took hold late last year, this hasn’t been the case in 2022 with losses sitting around 31%.

The company’s shares reached a multi-year high of 75.5 cents in early March, before giving up their astonishing gains.

On valuation grounds, Incannex presides a market capitalisation of around $549.97 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Rising cannabis share price.
Cannabis Shares

Why is the Cann share price smoking out the ASX by 20% today

Cann shares are in the green on Thursday.

Read more »

A woman wearing a pink blouse and straw hat holds up a cannabis leaf with tall green cannabis plants in the background
Cannabis Shares

Remember when ASX cannabis shares were smoking hot? Where are they now?

Newly legalised recreational and medicinal marijuana markets aren't getting the media hype they once did.

Read more »

A flaming orange arrow against a black background demonstrates the rising Pilbara Minerals share price today
Cannabis Shares

Why did the Little Green Pharma share price flame 23% higher today?

Little Green Pharma shares were on fire on Thursday...

Read more »

Young adult male farmer standing smiling in his indoor greenhouse full of herbal cannabis plants at a cannabis cultivation facility
Cannabis Shares

How have ASX cannabis shares been performing so far in 2022?

The sector has held its own during volatile times.

Read more »

Female doctor with a mask holds out hand in a stop gesture.
Healthcare Shares

Here’s why the Incannex (ASX:IHL) share price is on ice today

The company's shares are in a trading halt...

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Down 35% in a month, why there’s good news for the Creso Pharma (ASX:CPH) share price today

Cannabis derived CBD is being used to treat a growing list of ailments.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why did this ASX cannabis share burn 10% today?

Creso Pharma has announced a capital raise. Here are the details.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

This little-known ASX cannabis share has quietly gained 26% in a month to trade at all-time highs

Why is this ASX cannabis share having such a stellar month?

Read more »